Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.

@article{Fujimoto2010TripletCW,
  title={Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.},
  author={Nobukazu Fujimoto and Katsuyuki Kiura and Nagio Takigawa and Yoshiro Fujiwara and Shinichi Toyooka and Shigeki Umemura and Masahiro Tabata and Hiroshi Ueoka and Mitsune Tanimoto},
  journal={Acta medica Okayama},
  year={2010},
  volume={64 1},
  pages={33-7}
}
We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were < or = 70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1… CONTINUE READING